Read Books Online and Download eBooks, EPub, PDF, Mobi, Kindle, Text Full Free.
Targeted Therapies In Non Small Cell Lung Cancer
Download Targeted Therapies In Non Small Cell Lung Cancer full books in PDF, epub, and Kindle. Read online Targeted Therapies In Non Small Cell Lung Cancer ebook anywhere anytime directly on your device. Fast Download speed and no annoying ads. We cannot guarantee that every ebooks is available!
Book Synopsis Targeted Therapies for Lung Cancer by : Ravi Salgia
Download or read book Targeted Therapies for Lung Cancer written by Ravi Salgia and published by Springer. This book was released on 2019-06-26 with total page 238 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book contextualizes translational research and provides an up to date progress report on therapies that are currently being targeted in lung cancer. It is now well established that there is tremendous heterogeneity among cancer cells both at the inter- and intra-tumoral level. Further, a growing body of work highlights the importance of targeted therapies and personalized medicine in treating cancer patients. In contrast to conventional therapies that are typically administered to the average patient regardless of the patient’s genotype, targeted therapies are tailored to patients with specific traits. Nonetheless, such genetic changes can be disease-specific and/or target specific; thus, the book addresses these issues manifested in the somatically acquired genetic changes of the targeted gene. Each chapter is written by a leading medical oncologist who specializes in thoracic oncology and is devoted to a particular target in a specific indication. Contributors provide an in-depth review of the literature covering the mechanisms underlying signaling, potential cross talk between the target and downstream signaling, and potential emergence of drug resistance.
Book Synopsis Precision Medicine in Cancer Therapy by : Daniel D. Von Hoff
Download or read book Precision Medicine in Cancer Therapy written by Daniel D. Von Hoff and published by Springer. This book was released on 2019-06-17 with total page 283 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book presents the latest advances in precision medicine in some of the most common cancer types, including hematological, lung and breast malignancies. It also discusses emerging technologies that are making a significant impact on precision medicine in cancer therapy. In addition to describing specific approaches that have already entered clinical practice, the book explores new concepts and tools that are being developed. Precision medicine aims to deliver personalized healthcare tailored to a patient’s genetics, lifestyle and environment, and cancer therapy is one of the areas in which it has flourished in recent years. Documenting the latest advances, this book is of interest to physicians and clinical fellows in the front line of the war on cancer, as well as to basic scientists working in the fields of cancer biology, drug development, biomarker discovery, and biomedical engineering. The contributing authors include translational physicians with first-hand experience in precision patient care.
Book Synopsis Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners by : Marianne Davies
Download or read book Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners written by Marianne Davies and published by Springer. This book was released on 2019-07-16 with total page 120 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patients with non-small cell lung cancer (NSCLC). It will educate nurses and practitioners about the scope of therapy to assure safe and effective lung cancer treatment. In this era of personalized medicine, nurses and APP’s are responsible for guiding patients from diagnosis through treatment. This starts with the identification of patients that can benefit from these therapies, the key role of biopsy acquisition (ie. what to test, when and how often) and treatment selection based on the mutation identified. Readers will learn about the mechanisms of action, administration, potential adverse side effects and unique management strategies for these targeted agents. Lung cancer continues to be the leading cause of cancer death in the United States and worldwide. Recent advances in the identification of specific oncogenic mutations that drive cancer development, growth and metastasis have led to major paradigm shifts in lung cancer treatment. Sophisticated methods are required to identify specific mutations at the time of diagnosis. This book explains how molecularly targeted therapies have been developed that target these drivers. To date, several tyrosine kinase inhibitors have been approved to target the epidermal growth factor receptor (EGFR), EML4-ALK ,ROS1 and BRAF. Most recently, immune checkpoint inhibitors have been approved with some indication that efficacy may be enhanced for patients who overexpress PD-L1. While some driver mutations have been identified, there is ongoing investigation into additional mutations. In the case of driver mutations, lung cancers will develop resistance to therapy. This book provides nurses and APP’s with the mechanisms of resistance that have been identified such as T790 mutation and many others in the EGFR mutation, and shows how the next level of drug development is focused on identifying mechanisms of resistance and development of new agents that overcome these mutations. With this book in hand, nurses and practitioners will be able to navigate patients through this ever expanding field of lung cancer treatment.
Book Synopsis Targeted Therapies in Non-small Cell Lung Cancer by :
Download or read book Targeted Therapies in Non-small Cell Lung Cancer written by and published by . This book was released on 2005 with total page 40 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Targeted Therapies in Non-small-cell Lung Cancer by :
Download or read book Targeted Therapies in Non-small-cell Lung Cancer written by and published by . This book was released on 2008 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Fast Facts: Non-Small-Cell Lung Cancer by : Mary O'Brien
Download or read book Fast Facts: Non-Small-Cell Lung Cancer written by Mary O'Brien and published by Karger Medical and Scientific Publishers. This book was released on 2022-02-28 with total page 148 pages. Available in PDF, EPUB and Kindle. Book excerpt: Despite an overall decrease in tobacco use, lung cancer (80–85% of which is non-small-cell lung cancer [NSCLC]) is still the leading cause of cancer death in both men and women worldwide. Annual low-dose CT screening of high-risk individuals has the potential to detect early-stage tumors, which can usually be successfully treated with a combination of surgery, radiotherapy and chemotherapy and, in some cases, targeted therapy. However, most patients with NSCLC still present with advanced or metastatic disease. For these patients, initial therapy is guided by the tumor’s molecular characteristics and patient’s performance status. Targeted therapies have significantly improved clinical outcomes and, for some patients with no targetable genetic alterations, immunotherapy has demonstrated significant overall survival benefit. This insightful guide is designed to bring you up to speed with the latest developments and is important reading for all health professionals and medical trainees working in this fast-moving field. Table of Contents: • Prevention and screening • Diagnosis and staging • Surgery • Radiotherapy • Systemic therapy in non-metastatic NSCLC • Systemic therapy in advanced-stage/metastatic disease without a molecular driver • Personalized treatment in advanced NSCLC • Oligometastatic disease and brain metastases
Book Synopsis Molecular Targeted Therapy of Lung Cancer by : Yuichi Takiguchi
Download or read book Molecular Targeted Therapy of Lung Cancer written by Yuichi Takiguchi and published by Springer. This book was released on 2017-01-24 with total page 321 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book discusses the latest molecular targeted therapy of lung cancer including its evaluation and future directions. It clearly illustrates the initial dramatic effectiveness of molecular targeted therapy, recurrence of the disease, overcoming the wide variety of resistance mechanisms using new-generation molecular targeted agents and potential novel approaches. It also outlines the increasing necessity for new diagnostic technology and strategies for managing different adverse effects and novel methods for evaluating effectiveness and safety. Edited and authored by opinion leaders, Molecular Targeted Therapy of Lung Cancer provides a comprehensive overview of the disease and its treatments. It is a valuable resource for graduate students, post-doctoral fellows and faculty staff, as well as researchers involved in clinical and translational research on lung cancer, helping promote new ideas for further advances.
Book Synopsis Molecular Pathology of Lung Cancer by : Philip T. Cagle
Download or read book Molecular Pathology of Lung Cancer written by Philip T. Cagle and published by Springer Science & Business Media. This book was released on 2012-06-14 with total page 217 pages. Available in PDF, EPUB and Kindle. Book excerpt: As with other books in the Molecular Pathology Library Series, Molecular Pathology of Lung Cancer bridges the gap between the molecular specialist and the clinical practitioner, including the surgical pathologist who now has a key role in decisions regarding molecular targeted therapy for lung cancer. Molecular Pathology of Lung Cancer provides the latest information and current insights into the molecular basis for lung cancer, including precursor and preinvasive lesions, molecular diagnosis, molecular targeted therapy, molecular prognosis, molecular radiology and related fields for lung cancer generally and for the specific cell types. As many fundamental concepts about lung cancer have undergone revision in only the past few years, this book will likely be the first to comprehensively cover the new molecular pathology of lung cancer. It provides a foundation in this field for pathologists, medical oncologists, radiation oncologists, thoracic surgeons, thoracic radiologists and their trainees, physician assistants, and nursing staff.
Book Synopsis Advances in Systemic Therapy for Non-Small Cell Lung Cancer , An Issue of Thoracic Surgery Clinics by : Jessica Donington
Download or read book Advances in Systemic Therapy for Non-Small Cell Lung Cancer , An Issue of Thoracic Surgery Clinics written by Jessica Donington and published by Elsevier Health Sciences. This book was released on 2020-05-11 with total page 137 pages. Available in PDF, EPUB and Kindle. Book excerpt: This issue of Thoracic Surgery Clinics, guest edited by Drs. Jyoti Patel and Jessica Donington, is devoted to Advances in Systemic Therapy for Non-Small Cell Lung Cancer. Drs. Patel and Donington have assembled expert authors to review the following topics: Adjuvant and Neoadjuvant Immunotherapy; Combining Immunotherapy with Radiation in Lung Cancer; Adjuvant Chemotherapy; ALK Mutations; Molecular Targets Beyond the Big 3; Advances in Systemic Therapy; Liquid Biopsies in NSCLC; Combining Immunotherapy and Chemotherapy for NSCLC; ROS-1 Mutations; EGFR Mutations; and more!
Book Synopsis Histological Typing of Lung and Pleural Tumours by : W.D. Travis
Download or read book Histological Typing of Lung and Pleural Tumours written by W.D. Travis and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 139 pages. Available in PDF, EPUB and Kindle. Book excerpt: with contributions by Pathologists from 14 Countries
Book Synopsis Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs by : Umberto Malapelle
Download or read book Second Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological and Molecular Aspects of Novel Promising Drugs written by Umberto Malapelle and published by Frontiers Media SA. This book was released on 2017-08-29 with total page 86 pages. Available in PDF, EPUB and Kindle. Book excerpt: Lung cancer still remains a challenging disease with a higher mortality rate in comparison to other cancers. The discovery of oncogene addicted tumours and targeted therapies responsive to these targets lead to a meaningful change in the prognosis of these diseases. Unfortunately, these newer therapeutic options are reserved to a minor part of lung cancer patients harbouring specific mutations. In the so called wild type population, the first line options bring the median overall survival to go beyond 1 year, and in the population receiving the maintenance therapy over 16 months. Given these results, more than 60% of patients may receive a second line therapy with further opportunities to improve the length and quality of life. For patients not harbouring targetable DNA mutations newer options will be available for second line therapeutic schemes and two major assets seem to be promising: immune modulation and anti-angiogenetic agents. In particular, anti PD1/PDL1 antibodies, VEGFR antibodies and TKIs, these latter combined with standard chemotherapy docetaxel advance the median overall survival of 12 months. These drugs have a different mechanism of action, various adverse events and their activity is different depending on the types of population. However, the biomarkers’ activity and efficacy prediction are not fully or totally understood. In addition, also for patients with DNA targetable mutations new drugs seems to be promising for the use in the second line therapeutic protocols. In particular, drugs selectively directed against ALK translocation and mutational events and EGFR T790M secondary mutations seems to be very promising. In this Research Topic we critically discuss the older therapies and the historical development of second line, putting in to perspective the new agents available in clinical practice. We discuss their importance from a clinical point of view, but also consider and exploit the complex molecular mechanisms responsible of their efficacy or of the subsequently observed resistance phenomena. In this perspective, the undercovering and characterization of novel predictive biomarkers by NGS technology, the characterization of novel actors in the signal transduction pathway modulating the response of the cells, the optimization of new diagnostic tool as the evaluation of liquid biopsy and the implementation of more suitable pre-clinical models are crucial aspects dissected too. Nivolumab, nintedanib and ramucirumab probably will give the opportunity to improve the efficacy outcomes for the treatment of wild type tumours in second line therapeutic schemes, but many aspects should be debated in order that these agents are made available to patients, planning ahead a therapeutic strategy, beginning from the first line therapy, to the subsequent ones in a logical and affordable manner. As well, for treatment of mutated tumours, mutated EGFR irreversible inhibitors such as rociletinib and AZD9291, and ALK targeting drugs ceritinib and alectinib will also play an important role in the immediate future. Probably the right way is to give all the available opportunities to patients, but challenges and pitfalls should be carefully debated, and by launching this Research Topic we tried to give some practical insights in this changing landscape.
Book Synopsis TRAIL-receptor and Proteasome Targeted Therapies in Non-small Cell Lung Cancer by : Janet Henrieke Stegehuis
Download or read book TRAIL-receptor and Proteasome Targeted Therapies in Non-small Cell Lung Cancer written by Janet Henrieke Stegehuis and published by . This book was released on 2011 with total page 354 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Book Synopsis Lung Cancer and Personalized Medicine by : Aamir Ahmad
Download or read book Lung Cancer and Personalized Medicine written by Aamir Ahmad and published by Springer. This book was released on 2015-12-14 with total page 236 pages. Available in PDF, EPUB and Kindle. Book excerpt: This, the first of two volumes on personalized medicine in lung cancer, touches on the core issues related to the understanding of lung cancer—statistics and epidemiology of lung cancer—along with the incidence of lung cancer in non-smokers. A major focus of this volume is the state of current therapies against lung cancer—immune, targeted therapies against EGFR TKIs, KRAS, ALK, angiogenesis; the associated challenges, especially resistance mechanisms; and recent progress in targeted drug development based on metal chemistry. Chapters are written by some of the leading experts in the field, who provide a better understanding of lung cancer, the factors that make it lethal, and current research focused on developing personalized treatment plans. With a unique mix of topics, this volume summarizes the current state-of-knowledge on lung cancer and the available therapies.
Book Synopsis The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine by : Vera Hirsh
Download or read book The Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine written by Vera Hirsh and published by Frontiers Media SA. This book was released on 2015-10-20 with total page 142 pages. Available in PDF, EPUB and Kindle. Book excerpt: Lung cancer is the leading cause of cancer related mortality in Canada and USA. Majority of the patients present in advanced stage of the disease and of these only about 2% will be alive at 5 years. NSCLC is the most common form of lung cancer, accounting for approximately 87% of cases. Systemic chemotherapies have been used to treat metastatic NSCLC for decades, but the improvements of outcomes have reached a plateau. Recent advances in understanding signalling pathways for malignant cells, their interconections,the importance of various receptors and biomarkers and the interplay between various oncogenes have led to the development of targeted treatments that are improving both efficacy and safety of the treatments. Knowledge about the advantages of treatments with the targeted agents in metastatic NSCLC is growing rapidly. Combining various targeted agents or sequencing them properly will be important in the era of personalised medicine and overcoming development of the resistence to various targeted agents will be challenging. The importance of a team work,from the diagnosis through various treatments, to supportive care, from the interventional radiologists, pneumologists or surgeons, who have to obtain a satisfactory tumor tissue specimen, to pathologists, radiation and medical oncologists, to supportive care specialists, will be described in our publications. We will cover completely present and future approaches to personalised medicine in this rapidly evolving field of metastatic NSCLC.
Book Synopsis Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine by : Vera Hirsh
Download or read book Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine written by Vera Hirsh and published by Frontiers Media SA. This book was released on 2018-01-24 with total page 95 pages. Available in PDF, EPUB and Kindle. Book excerpt: Lung cancer remains a major cause of death in of both women and men in our society. Lung cancer treatment paradigms have changed enormously as we’ve started to understand the genetic complexity and the multiple driver mutations influencing the disease. Therapeutics directed towards, or to inhibit signaling pathways has resulted in increased life spans for our patients. Over the last two decades, we have gone from simple chemotherapy used to treat all, to a personalized medicine approach for the majority. For non-small cell lung cancer patients without driver mutations, the world of immune oncology has arrived. These improved long-term outcomes mean that now our lung cancer patients can live with their cancers, but without progression. The aim of this book is to catalogue the current state of knowledge for the many facets of advanced lung cancer. It describes current treatment approaches for driver mutations, rare mutations, and rare thoracic malignancies such as neuroendocrine tumors. Most importantly, this book addresses the topics of palliative treatment and care which allow our patients to enjoy longer survival with the highest quality of life. We hope you enjoy this e-book. The future is brighter for lung cancer patients and as lung cancer specialists; we finally feel sense optimism about treatment options for our patients.
Book Synopsis Targeted Therapies in Oncology by : Giuseppe Giaccone
Download or read book Targeted Therapies in Oncology written by Giuseppe Giaccone and published by CRC Press. This book was released on 2007-09-25 with total page 426 pages. Available in PDF, EPUB and Kindle. Book excerpt: Targeted therapy is one of the most burgeoning areas of development in cancer research. Increasing knowledge in tumor formation and growth at the molecular level has generated a broad array of therapeutic options, including signal transduction inhibition, anti-angiogenic and anti-vascular agents, cell cycle inhibitors, telomerase and telomere inter
Book Synopsis Targeted Therapies in Non-small Cell Lung Cancer by : Nancy G. Houlihan
Download or read book Targeted Therapies in Non-small Cell Lung Cancer written by Nancy G. Houlihan and published by . This book was released on 2007 with total page 40 pages. Available in PDF, EPUB and Kindle. Book excerpt: Educational objectives: After completing this independent study, the participant will be able to: Discuss the rationale for targeting the human epidermal growth factor family of receptors in cancer; Describe the role of HER1/EGFR in malignancy; Summarize the clinical data regarding the role of HER1/EGFR inhibitors; Identify key elements related to symptom management and patient education related to HER1/EGFR therapies in non-small cell lung cancer. - p. 1.
